BusinessPostCorner.com
No Result
View All Result
Wednesday, July 16, 2025
  • Home
  • Business
  • Finance
  • Accounting
  • Tax
  • Management
  • Marketing
  • Crypto News
  • Human Resources
BusinessPostCorner.com
  • Home
  • Business
  • Finance
  • Accounting
  • Tax
  • Management
  • Marketing
  • Crypto News
  • Human Resources
No Result
View All Result
BusinessPostCorner.com
No Result
View All Result

Moderna wins case in patent dispute with Pfizer and BioNTech over Covid jab

May 17, 2024
in Finance
Reading Time: 3 mins read
A A
0
Moderna wins case in patent dispute with Pfizer and BioNTech over Covid jab
ShareShareShareShareShare

Unlock the Editor’s Digest for free

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.

Moderna has won a case at the European Patent Office in its dispute with Pfizer and BioNTech over its Covid-19 vaccine, in a boon for the mRNA-vaccine maker in its ongoing legal fight to recoup pandemic profits from its rivals.

The decision by the EPO’s Opposition Division on Thursday to uphold the validity of one of two disputed patents is a boost for Moderna, which has faced several setbacks in its legal battle over Pfizer and BioNTech’s bestselling Comirnaty vaccine.

“We are pleased to announce that the European Patent Office decided to maintain the validity of Moderna’s EP949 patent, one of the key patents currently asserted against Pfizer and BioNTech in various European national courts,” the company told the Financial Times.

Pfizer has a nine-month window to lodge an appeal, which it said it may do, while BioNTech did not immediately respond to a request for comment. The EPO handed down an oral verdict on Thursday and is expected to publish a written decision in the coming months.

Moderna is pursuing Pfizer and BioNTech for a share of their profits from the Covid-19 vaccines in several courts across Europe and the US. The company has said that the Comirnaty vaccine infringes two of its patents.

Pfizer and BioNTech have countersued, alleging that the Moderna patents, filed in 2011 and 2016, are invalid.

Between them, Moderna, Pfizer and BioNTech — the leading Covid-19 vaccine makers — have generated billions in revenues from coronavirus shots, making $73.2bn in 2022 alone.

But the share prices of all three pharma groups have been hit as the pandemic has receded and demand for vaccines has waned.

The 949 patent relates to how mRNA is tweaked in the body to lower the immune response when introduced in the form of the vaccine. While pivotal to Moderna’s Covid-19 drug, the feature could also be applied to future mRNA-based treatments.

The EPO said that Moderna’s 949 patent “was maintained in amended form”.

Moderna last year lost a validity challenge in the EPO over an alternative patent, known as 565, which covers the use of mRNA technology specifically targeted at preventing coronavirus and other respiratory diseases. Moderna is appealing that decision.

National courts will continue to make rulings on the validity of the patent and whether it was infringed by Pfizer and BioNTech. They will also decide on any penalty to be paid.

Recommended

The companies are awaiting a verdict on proceedings in London, which will also assess the legal impact of a pledge made by Moderna not to enforce its intellectual property rights while the pandemic continued.

Dutch, Belgian, German and Irish courts are also among European those assessing the validity of the patents, for which the EPO ruling could prove influential.

The Netherlands declared the 949 patent invalid in December proceedings but Moderna is appealing this ruling and litigation is likely to drag on.

Moderna has previously said it is not seeking to prevent the use of the Comirnaty vaccine.

Pfizer said: “Irrespective of the outcome of this legal matter, we will continue to manufacture and supply the BioNTech/Pfizer Covid-19 vaccine in line with our agreements and established supply schedules, in support of public health.”

Credit: Source link

ShareTweetSendPinShare
Previous Post

On the move: Forvis adds assurance partner

Next Post

Wine industry nears crisis as sales drop

Next Post
Wine industry nears crisis as sales drop

Wine industry nears crisis as sales drop

California pampers its chickens and Americans pay the price, Trump argues in new DOJ lawsuit

California pampers its chickens and Americans pay the price, Trump argues in new DOJ lawsuit

July 11, 2025
Elon Musk’s Tesla finally sets a shareholder meeting amid doubts about his long-denied  billion pay package

Elon Musk’s Tesla finally sets a shareholder meeting amid doubts about his long-denied $56 billion pay package

July 10, 2025
How we saved hundreds on our family summer holiday

How we saved hundreds on our family summer holiday

July 12, 2025
A space has opened up in British politics

A space has opened up in British politics

July 11, 2025
BlackRock’s Q2 Digital Asset Inflows Reach B, Total AUM Hits .6B

BlackRock’s Q2 Digital Asset Inflows Reach $14B, Total AUM Hits $79.6B

July 15, 2025
Shift from budget gatekeeper to strategic partner

Shift from budget gatekeeper to strategic partner

July 10, 2025
BusinessPostCorner.com

BusinessPostCorner.com is an online news portal that aims to share the latest news about following topics: Accounting, Tax, Business, Finance, Crypto, Management, Human resources and Marketing. Feel free to get in touch with us!

Recent News

JPMorgan Chase is rolling out a new fee structure that could ‘cripple’ crypto and fintech startups, executives warn

JPMorgan Chase is rolling out a new fee structure that could ‘cripple’ crypto and fintech startups, executives warn

July 16, 2025
Elliptic Report Finds Cross-Chain Crime Up 200 – Here’s Where Hackers Hide Now

Elliptic Report Finds Cross-Chain Crime Up 200 – Here’s Where Hackers Hide Now

July 16, 2025

Our Newsletter!

Loading
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • DMCA

© 2023 businesspostcorner.com - All Rights Reserved!

No Result
View All Result
  • Home
  • Business
  • Finance
  • Accounting
  • Tax
  • Management
  • Marketing
  • Crypto News
  • Human Resources

© 2023 businesspostcorner.com - All Rights Reserved!